炎症性肠病的现代先进治疗:实践考量与定位
过去5年炎症性肠病治疗药物显著扩充,包括口服小分子JAK抑制剂(乌帕替尼、托法替布)、S1P受体调节剂(奥扎尼莫德、依曲西莫德)及选择性IL-23拮抗剂(瑞莎珠单抗、米吉珠单抗)。本综述讨论这些新疗法的实际应用,聚焦真实世界有效性与安全性、给药与监测、特殊情形(妊娠、合并免疫介导疾病、住院急性重症UC、围手术期),并提出临床定位方法。
要点
- JAK抑制剂(乌帕替尼、托法替布)、S1P受体调节剂(奥扎尼莫德、依曲西莫德)和选择性IL-23拮抗剂(瑞莎珠单抗、米吉珠单抗)已获批用于IBD。
- 综述聚焦真实世界有效性与安全性、给药与监测考量及特殊情形用药。
- 作者提出基于药物比较有效性与安全性、患者并发症风险与偏好的定位方法。
核心结论
- 作者提出应综合药物比较有效性与安全性、患者疾病与治疗相关并发症风险及偏好来定位这些新疗法。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 过去5年IBD治疗药物显著扩充,包括口服小分子JAK抑制剂、S1P受体调节剂和选择性IL-23拮抗剂。
- 乌帕替尼获批用于克罗恩病和溃疡性结肠炎,托法替布获批用于溃疡性结肠炎。
- 奥扎尼莫德和依曲西莫德均获批用于溃疡性结肠炎。
- 瑞莎珠单抗获批用于克罗恩病,米吉珠单抗获批用于溃疡性结肠炎。
- 这些疗法的有效性和安全性存在差异。
临床怎么用
- 综述讨论这些新疗法的实际使用,聚焦真实世界有效性与安全性数据、给药与监测考量。
- 特殊情形包括妊娠、合并免疫介导疾病、住院急性重症UC患者及围手术期。
- 作者提出依靠仔细整合药物比较有效性与安全性、患者并发症风险与偏好来定位这些疗法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic armamentarium for management of inflammatory bowel diseases has expanded dramatically in the last 5 years, with the introduction of several medications with different mechanisms of action. These include the oral small molecule drugs Janus kinase inhibitors (including upadacitinib, approved for Crohn's disease and ulcerative colitis [UC], and tofacitinib, approved for UC) and sphingosphine 1-phosphate receptor modulators (ozanimod and etrasimod, both approved for UC), and biologic agents, such as selective interleukin-23 antagonists (risankizumab approved for Crohn's disease, and mirikizumab approved for UC). The efficacy and safety of these therapies vary. In this review, we discuss practical use of these newer advanced therapies focusing on real-world effectiveness and safety data, dosing and monitoring considerations, and special situations for their use, such as pregnancy, comorbid immune-mediated disease, use in hospitalized patients with acute severe UC, and in the perioperative setting. We also propose our approach to positioning these therapies in clinical practice, relying on careful integration of the medication's comparative effectiveness and safety in the context of an individual patient's risk of disease- and treatment-related complications and preferences.
引用
- Fudman DI, McConnell RA, Ha C, et al. Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. Clin Gastroenterol Hepatol. 2024. PMID: 39147217. doi:10.1016/j.cgh.2024.06.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。